Filing Flows › Health Care › Aclaris Therapeutics (ACRS)
Aclaris Therapeutics (ACRS) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 5, 2026 · Aclaris Therapeutics (ACRS) Q3 2026 earnings results →
Q3 2026 Revenue down 55% year over year to $1.5M
Aclaris Therapeutics made $1.5M in Q3 2026 (-55% Y/Y): Licensing $1.2M, Contract research $300K. Operating margin n/m, net loss $18.5M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $1.5M in Q3 2026, down 55% year over year and down 9% from the previous quarter. Licensing was the largest line at 80% of revenue. Licensing lost $1.6M year over year (down 58%), 90% of the total change.
Operating costs exceeded revenue by $21.3M, an operating margin of -1441.2%. Total costs grew 12% against a revenue fall of 55%. The fastest-growing cost line was General & admin (+24%). The quarter ended with a net loss of $18.5M, narrower than the previous quarter's $21.5M loss.
Operating cash flow was −$24.1M. Non-cash charges added back $100K of depreciation and amortization and $3.0M of share-based compensation. Working capital and other items used $8.7M. Capital expenditures of $13K exceeded it, leaving free cash flow of −$24.1M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 5, 2026 | $1.5M | -55% | n/m | −$18.5M | −$24.1M |
| Q2 2026 | 10-Q | Aug 6, 2026 | $1.6M | -8% | n/m | −$21.5M | −$19.8M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Aclaris Therapeutics
We are a clinical-stage biopharmaceutical company focused on discovering and developing novel small and large molecule product candidates for immuno-inflammatory diseases. Our proprietary KINect drug discovery platform coupled with our integrated discovery approach to small and large molecules enables us to identify and advance product candidates designed to have superior target affinity, specificity and potency. We are seeking to identify and consummate transactions with third-party partners to further develop, obtain marketing approval for and/or commercialize our novel product candidates.
In its own words, from its 10-K, filed Feb 26, 2026.
Aclaris Therapeutics against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -55% against the peers' median +7%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| ACRS Aclaris Therapeutics | Q3 2026 | $1.5M | -55% | n/m |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Aclaris Therapeutics 10-Q on SEC EDGAR · CIK 1557746 · Pharmaceutical Preparations
Guidance and outlook
13F: who owns ACRS and who is buying
More on ACRS
- How Aclaris Therapeutics makes money: revenue by segment
- Aclaris Therapeutics next earnings date and what analysts expect
- Aclaris Therapeutics stock forecast, price target and fair value
- Who owns Aclaris Therapeutics stock: holders, funds and Congress trades
- Aclaris Therapeutics guidance and outlook
- Aclaris Therapeutics recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results